Ab­b­Vie and San­doz agree to drop court spat over Rin­voq patents

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq.

San­doz ad­mit­ted the Rin­voq patents as­sert­ed against it are “en­force­able, valid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER